Literature DB >> 17418683

The renin-angiotensin system and diabetic nephropathy.

Susan B Gurley1, Thomas M Coffman.   

Abstract

The renin-angiotensin system (RAS) has key regulatory functions for blood pressure and fluid homeostasis. In addition, dysregulation of the system can have maladaptive effects to promote tissue injury in chronic diseases such as hypertension, heart failure, and kidney disease. These actions for the RAS to promote disease pathogenesis are especially apparent in diabetic nephropathy, the most common cause of end-stage renal disease in the United States. Evidence of a role for the RAS in diabetic nephropathy comes from studies in animal models and randomized clinical trials showing efficacy of angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers to slow the progression of renal disease. Widespread applications of these therapies to a range of renal diseases may have contributed to the recent reduction in the incidence rates for end-stage renal disease. We provide a general review of the RAS and its role in diabetic nephropathy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17418683     DOI: 10.1016/j.semnephrol.2007.01.009

Source DB:  PubMed          Journal:  Semin Nephrol        ISSN: 0270-9295            Impact factor:   5.299


  58 in total

Review 1.  Nuclear receptors in renal disease.

Authors:  Moshe Levi
Journal:  Biochim Biophys Acta       Date:  2011-04-14

Review 2.  Nuclear hormone receptors in diabetic nephropathy.

Authors:  Xiaoxin X Wang; Tao Jiang; Moshe Levi
Journal:  Nat Rev Nephrol       Date:  2010-04-27       Impact factor: 28.314

Review 3.  Activation of the renal renin-angiotensin system in diabetes--new concepts.

Authors:  János Peti-Peterdi; Jung Julie Kang; Ildiko Toma
Journal:  Nephrol Dial Transplant       Date:  2008-07-20       Impact factor: 5.992

4.  FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity.

Authors:  Xiaoxin X Wang; Dong Wang; Yuhuan Luo; Komuraiah Myakala; Evgenia Dobrinskikh; Avi Z Rosenberg; Jonathan Levi; Jeffrey B Kopp; Amanda Field; Ashley Hill; Scott Lucia; Liru Qiu; Tao Jiang; Yingqiong Peng; David Orlicky; Gabriel Garcia; Michal Herman-Edelstein; Vivette D'Agati; Kammi Henriksen; Luciano Adorini; Mark Pruzanski; Cen Xie; Kristopher W Krausz; Frank J Gonzalez; Suman Ranjit; Alexander Dvornikov; Enrico Gratton; Moshe Levi
Journal:  J Am Soc Nephrol       Date:  2017-10-31       Impact factor: 10.121

5.  SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy: SGLT2 PROTEIN INHIBITION DECREASES RENAL LIPID ACCUMULATION, INFLAMMATION, AND THE DEVELOPMENT OF NEPHROPATHY IN DIABETIC MICE.

Authors:  Xiaoxin X Wang; Jonathan Levi; Yuhuan Luo; Komuraiah Myakala; Michal Herman-Edelstein; Liru Qiu; Dong Wang; Yingqiong Peng; Almut Grenz; Scott Lucia; Evgenia Dobrinskikh; Vivette D D'Agati; Hermann Koepsell; Jeffrey B Kopp; Avi Z Rosenberg; Moshe Levi
Journal:  J Biol Chem       Date:  2017-02-14       Impact factor: 5.157

Review 6.  Key metalloproteinase-mediated pathways in the kidney.

Authors:  Tammo Ostendorf; Andreas Ludwig; Justyna Wozniak; Jürgen Floege
Journal:  Nat Rev Nephrol       Date:  2021-04-20       Impact factor: 28.314

Review 7.  From fibrosis to sclerosis: mechanisms of glomerulosclerosis in diabetic nephropathy.

Authors:  Ying Qian; Eva Feldman; Subramanian Pennathur; Matthias Kretzler; Frank C Brosius
Journal:  Diabetes       Date:  2008-06       Impact factor: 9.461

8.  Health Education and General Practitioner Training in Hypertension Management: Long-Term Effects on Kidney Function.

Authors:  Tazeen H Jafar; John C Allen; Imtiaz Jehan; Aamir Hameed; Seyed Ehsan Saffari; Shah Ebrahim; Neil Poulter; Nish Chaturvedi
Journal:  Clin J Am Soc Nephrol       Date:  2016-05-19       Impact factor: 8.237

9.  Role of upstream stimulatory factor 2 in diabetic nephropathy.

Authors:  Shuxia Wang
Journal:  Front Biol (Beijing)       Date:  2015-05-13

Review 10.  Can we target tubular damage to prevent renal function decline in diabetes?

Authors:  Joseph V Bonventre
Journal:  Semin Nephrol       Date:  2012-09       Impact factor: 5.299

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.